Objective. Biomarkers may be helpful in screening patients with psoriasis for PsA. Our purpose was to identify serum biomarkers for psoriasis and PsA.
Introduction
Psoriasis is a chronic inflammatory skin disease affecting $2% of the general population [1] . Psoriasis is associated with significant morbidity and disability, and decreased quality of life [1] . About 30% of the patients with psoriasis have PsA that may affect both axial and peripheral joints [2, 3] . PsA contributes additional morbidity to patients who have psoriasis [4] . Studies from dermatology clinics suggest that there is a high prevalence of undiagnosed PsA in patients with psoriasis [4, 5] . Identifying soluble biomarkers that identify PsA in patients with psoriasis may help in early diagnosis, prevent disability and improve quality of life and function [6] .
We hypothesized that serum biomarkers of inflammation, bone and cartilage damage are associated with PsA and distinguish patients with PsA from those with psoriasis alone. We therefore aimed to detect biomarkers associated with PsA by comparing serum biomarker levels in a selected sample of patients with psoriasis, PsA and healthy controls.
Patients and methods

Patient selection and assessment
We recruited 52 patients with chronic plaque psoriasis, 26 of whom also had PsA, and 26 healthy controls. All patients with psoriasis had the diagnosis of psoriasis confirmed by a dermatologist. They were examined by a rheumatologist and 26 satisfied the ClASsification of Psoriatic ARthritis (CASPAR) study group criteria [7] . In the remaining patients, PsA was excluded by clinical examination. Laboratory investigations and radiographs were done only if warranted. Controls were recruited from healthy volunteers who did not have psoriasis or inflammatory arthritis. Patients with psoriasis and PsA were group matched for age, sex and psoriasis duration, whereas controls were matched for age and sex. None of the patients was treated with biological agents at the time of or before study participation, since these agents have been shown to suppress soluble biomarkers [8] . Three patients with psoriasis were on systemic therapy (MTX 1, retinoids 2). The rest were on topical agents and phototherapy. Fourteen PsA patients were on diseasemodifying agents (MTX 10, others 4) and the remaining 12 were on anti-inflammatory agents alone. We thus had three groups of well-characterized subjects-chronic plaque psoriasis without PsA, PsA and healthy controls. Blood samples were drawn at the time of clinical assessment, processed immediately, and serum aliquots were stored at À80 C until biomarker analyses.
Biomarkers
Candidate biomarkers were identified through literature review. Since PsA is an inflammatory disease that leads to joint destruction, we specifically researched biomarkers specific for chronic skin and joint inflammation, especially those specific for the recently described Th17 pathway, as well as joint damage. The following biomarkers related to inflammation were selected: the acute-phase reactant highly sensitive CRP (hsCRP), the cytokines IL-12, the p40 subunit of IL- [9] [10] [11] [12] [13] [14] [15] [16] . All 78 serum samples were then simultaneously analysed for these 12 biomarkers using commercially available ELISA kits according to manufacturers' instructions. The serum levels of IL-12 and IL-17 were below detectable levels in most samples (69 and 71, respectively, out of a total of 78 serum samples). Therefore, these two biomarkers were excluded from further analyses.
Statistical analyses
Logistic regression models were fit with disease classification as the outcome using biomarkers as explanatory variables while controlling for age and sex. For each disease group, receiver operating characteristic (ROC) curves were constructed to investigate how biomarker data can best be used to classify patients into disease groups. The accuracy of the classification of patients was summarized using the area under the ROC curve. The biomarkers included in the analyses were hsCRP, IL-12p40, RANKL, OPG, TNFSF14, MMP-3, C1-2C and COMP as well as the CPII : C2C ratio. This ratio rather than the individual level of the biomarkers was chosen since the ratio is more informative than either biomarker alone [16] . Univariate, full multivariate and reduced multivariate logistic regression models were used to identify which biomarkers were independently associated with disease class. We first combined patients with psoriasis and PsA into one group to identify biomarkers for 'psoriatic disease'. Subsequently, effects of markers on patients with psoriasis alone vs controls and patients with PsA vs controls were compared using polychotomous logistic regression, a regression technique useful for discrete responses with three or more categories. Given this framework, we can formally test whether the associations between markers and disease status are similar between the two types of disease groups. This test is based on a test of the null hypothesis that the effects are similar (i.e. a test of homogeneous effects) and P-values provide the significance level of differences between groups. Tests can also, of course, be used to test for the relationship between markers and particular disease classifications [17] . Finally, biomarkers that differentiate PsA from psoriasis were identified by comparing patients with PsA with those with psoriasis alone. All study subjects' written consent was obtained according to the Declaration of Helsinki. The study was approved by the University Health Network's Research Ethics Board.
Results
The demographics, disease characteristics and biomarker levels of recruited subjects are given in Table 1 . To identify biomarkers associated with 'psoriatic disease', we compared the levels in patients (psoriasis and PsA combined) with controls. Results of the univariate and multivariate analyses adjusted for age and sex are shown in Table 2 . The results of the analyses showed that increased serum levels of RANKL, TNFSF14, MMP-3 and COMP independently increased the odds of having psoriatic disease (all P < 0.05).
The results of the polychotomous logistic regression analysis to identify biomarkers that have differential association among the three subject groups (psoriasis, PsA and controls) are shown in Table 3 . This statistical technique allows one to simultaneously investigate the differences between the three groups using logistic regression. The homogeneity P-values obtained indicate the differences among the three groups (psoriasis, PsA and controls) when modelling psoriasis and PsA separately, controlling for age, sex and the other biomarkers listed. The P-values associated within each group indicate the significance of differences between the patient group (psoriasis and PsA) and the reference group (controls). We show that hsCRP, OPG, TNFSF14, MMP-3 and CPII : C2C ratio are biomarkers that are significantly different between the three groups. Increased hsCRP, RANKL, OPG and MMP-3 are independently associated with PsA, whereas increased RANKL, TNFSF14 and COMP as well as decreased CPII : C2C ratio are independently associated with psoriasis alone.
To further investigate biomarkers of PsA in patients with psoriasis, we compared the levels of the biomarkers between patients with PsA and psoriasis. The results of this logistic regression analysis are given in Table 4 . The results confirm that increased levels of the biomarkers hsCRP, OPG, MMP-3 and the CPII : C2C ratio are independently associated with the presence of PsA when compared with patients with psoriasis alone. ROC analysis using this reduced model showed an area under the curve (AUC) of 0.904. The full model had an AUC of 0.941 (Fig. 1) . Exploratory analyses showed that there were no significant differences in the mean levels of the biomarkers between patients on treatment and those not. Biomarker levels were also compared between patients on treatment and those not with MTX. Patients on MTX had lower levels of C2C compared with those not on MTX (122.6 vs 143.1 ng/ml, respectively, P = 0.036). There were no significant differences in the other biomarkers tested. IL-12 and C1-2C levels were higher in patients with a higher number of tender and/or swollen joints, whereas TNFSF14 levels were lower. COMP levels correlated with psoriasis area and severity index (PASI) scores. None of the biomarkers was associated with joint damage (assessed by the modified Steinbroker's method) or the presence of axial arthritis (presence of at least unilateral Grade 2 radiographic sacroiliitis; data not shown) [18] .
Discussion
A biomarker may be defined as a factor that is objectively measured and serves as a surrogate marker of physiological or pathological biological processes or pharmacological responses to a therapeutic intervention [19] . Biomarkers have a number of applications including diagnosis, staging or classification of the extent of disease, indicating disease prognosis, and predicting and monitoring the clinical response to an intervention [19] . PsA is an inflammatory arthritis associated with psoriasis that most often develops in patients who already have chronic plaque psoriasis [2] . PsA further worsens quality of life and function of patients with psoriasis [4] . Estimates of the prevalence of PsA in patients with psoriasis vary widely [20] . However, there is agreement that there is a high prevalence of musculoskeletal symptoms in patients with psoriasis. Recent studies have shown a high prevalence of undiagnosed PsA in patients with psoriasis seen in dermatology clinics [4, 5] . Identifying biomarkers for PsA in patients with psoriasis will help to identify patients at increased risk of having PsA so that they may be referred by dermatologists or primary care physicians for further evaluation by a rheumatologist. This will help in early diagnosis, prevent disability and improve quality of life and function in patients with psoriasis. Therefore, we aimed to identify soluble biomarkers for PsA in patients who have cutaneous psoriasis. We chose to test biomarkers that have relevance to inflammation, bone and cartilage damage. The results of this pilot study indicate that hsCRP, OPG, MMP-3 and the CPII : C2C ratio are biomarkers for PsA in patients with psoriasis. CRP is an acute-phase reactant [9] . Classical acutephase reactants such as ESR and CRP are normal in up to 50% of patients with PsA. The hsCRP assays were developed to detect CRP levels <5 mg/l. The hsCRP is a more sensitive marker of inflammation [21] . hsCRP levels are elevated in patients with psoriasis with or without PsA [22] . Here, we show that hsCRP levels are higher in PsA patients compared with those with psoriasis alone. Thus, hsCRP is a biomarker of PsA in patients with psoriasis and indicates additional inflammatory burden. OPG is a cytokine that inhibits osteoclast differentiation and promotes bone formation. Synovial tissue from PsA has been shown to express high levels of RANKL and very low quantities of OPG providing a possible mechanism for bone erosions in PsA [13] . Serum OPG levels have been found to be elevated in patients with PsA [23] . OPG is potentially a marker of periostitis and new bone formation, which is the only characteristic feature of PsA that differentiates it from other inflammatory joint diseases [7] . We show that an increased level of OPG is a marker of PsA in patients with psoriasis and may indicate the presence of new bone formation. MMP-3 or stromelysin-1 is an enzyme that plays a part in the destruction of cartilage and bone in rheumatic diseases characterized by synovitis, such as RA, PMR, PsA and acute crystal arthritis [15] . In AS, serum MMP-3 levels correlate with disease activity and the levels are high in those with very active disease [24, 25] . Serum MMP-3 levels decrease with treatment with infliximab and the concentration of serum MMP-3 is an independent predictor of structural damage progression in AS [26] . We have now shown that an elevated MMP-3 level is associated with PsA in patients with psoriasis. Cartilage destruction and remodelling are features of inflammatory arthritis. The products of cartilage synthesis and destruction are released into the serum during this process. These markers can be measured in the sera and may serve as biomarkers of arthritis. The articular cartilage is composed of a Type II collagenbased fibrillar network complexed with aggrecan, a proteoglycan [27] . Excessive and progressive cleavage of Type II collagen by collagenases generates the neoepitopes Col2-3/4C long mono (C2C) and Col2-3/4C short (C1-2C) [16] . As Type II collagen is degraded, chondrocytes up-regulate their synthesis of procollagen. The rate of synthesis of Type II collagen is directly proportional to the content of the CPII in cartilage. The CPII : C2C ratio reflects the balance between Type II collagen synthesis and degradation. The balance is more informative than either biomarker alone [16] . In AS, CPII:C2C was found to be elevated and correlated with CRP levels [28] . FIG. 1 ROC curves showing the AUCs for both the full and reduced logistic regression models comparing patients with PsA (n = 26) with those with psoriasis alone ( n = 26).
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We show that an elevated CPII : C2C ratio is an independent biomarker for PsA in patients with psoriasis and may, like OPG, indicate new bone formation. Thus, the four biomarkers that distinguish patients with PsA from those with psoriasis alone have biological relevance and have previously been shown to be biomarkers for AS, a disease that has many features in common with PsA.
We have also been able to identify biomarkers for 'psoriatic disease'. RANKL, TNFSF14, MMP-3 and COMP distinguish patients with disease from normal controls. RANKL and TNFSF14 are molecules in the TNF receptor family. RANKL plays a pathogenic role in inflammatory diseases associated with bone loss [29] . TNFSF14 also plays a pathogenic role in diseases such as RA, AS and IBD [14, 30, 31] . These T-cell cytokines are biomarkers for psoriatic disease and their role in the pathogenesis of psoriasis and/or PsA needs further investigation. Although associated with 'psoriatic disease', TNFSF14 is associated with psoriasis rather than PsA (Table 3) . RANKL was associated with both disease subgroups and there was no statistically significant difference between patients with psoriasis alone and those with PsA. The association of MMP-3 was greater with PsA than psoriasis alone. COMP levels were elevated in patients with 'psoriatic disease' and in patients with psoriasis alone but not in PsA. This is unlikely to be due to the presence of subclinical arthritis as suggested by Skoumal et al. [32] , since PsA patients had lower levels. Alternatively, COMP may be a biomarker for cutaneous psoriasis since it is expressed in skin fibroblasts and shows promise as a biomarker in SSc [33, 34] . Although fibroblasts do not seem to have a direct pathogenic role in psoriasis, they contribute to psoriasis pathogenesis by expressing molecules involved in T-cell recruitment and activation [35] . Psoriatic fibroblasts are in a hyperactive state in terms of production of extracellular matrix proteins and altered proliferative response to serum factors [35] . Thus, it is possible that activated psoriatic fibroblasts are responsible for excessive COMP production in psoriasis, and COMP may be a biomarker for psoriasis activity. This requires further investigation.
Thus, the results of this pilot study in a small selected group of carefully phenotyped patients with psoriasis, PsA and controls show that there are soluble biomarkers that distinguish patients with PsA from those with psoriasis alone. The results have to be validated in larger crosssectional studies. The role of these biomarkers in diagnosis and prognosis will need to be addressed in well-defined longitudinal studies in patients with psoriasis alone and those with early PsA.
Rheumatology key messages
. There is high prevalence of PsA in patients with psoriasis seen in dermatology clinics. . Soluble biomarkers may help to differentiate patients with PsA from those with cutaneous psoriasis alone.
